Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | MLYCD | O95822 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5703500 | 0.85 | HPGD (0.73) | HPGDALDH1A1MAPTMLYCDL3MBTL1 | |
| SCHEMBL29953564 | 0.85 | HDAC1 (0.59) | HPGDALDH1A1MAPTL3MBTL1LMNA | |
| SCHEMBL12538103 | 0.85 | MLYCD (0.58) | HPGDALDH1A1MLYCD | |
| SCHEMBL490705 | 0.83 | LPL (0.44) | HPGDALDH1A1MAPTMLYCDL3MBTL1 | |
| SCHEMBL6352172 | 0.82 | EGFR (0.57) | HPGDALDH1A1MLYCD | |
| SCHEMBL1820475 | 0.80 | LPL (0.41) | HPGDALDH1A1MAPTMLYCDL3MBTL1 | |
| SCHEMBL4949859 | 0.80 | LPL (0.54) | HPGDMLYCD | |
| SCHEMBL1771787 | 0.79 | HPGD (0.63) | HPGDALDH1A1MAPTL3MBTL1LMNA | |
| SCHEMBL29951715 | 0.79 | HPGD (0.63) | HPGDALDH1A1MAPTL3MBTL1LMNA | |
| SCHEMBL1806308 | 0.78 | HPGD (0.63) | HPGDALDH1A1MAPTMLYCDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024016826-A1 | 6-POSITION SUBSTITUTED DIHYDROBENZO[E][1,2,3]OXATHIAZINE 2,2-DIOXIDE COMPOUND, PREPARATION THEREFOR, AND USE THEREOF | 杭州市第七人民医院 | 2024-01-25 | — | — | WO | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | claimed |
| CN-115232090-A | 6-substituted dihydrobenzo [ e ] [1,2,3] oxathiazine 2,2-dioxide compound and preparation and application thereof | 杭州市第七人民医院 | 2022-10-25 | — | — | CN | claimed |
| WO-2022159439-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2022-07-28 | — | — | WO | claimed |
| US-20250386657-A1 | PHOTOELECTRIC CONVERSION ELEMENT | ENECOAT TECH CO LTD (JP) | 2025-12-18 | — | — | US | disclosed |
| EP-4646077-A1 | PHOTOELECTRIC CONVERSION ELEMENT | Enecoat Technologies Co., Ltd. (JP) | 2025-11-05 | — | — | EP | disclosed |
| US-12421257-B2 | Compositions and methods for inhibiting group II intron RNA | YALE UNIVERSITY (US) | 2025-09-23 | — | — | US | disclosed |
| WO-2025110210-A1 | PHOTOELECTRIC CONVERSION ELEMENT AND SOLAR CELL MODULE | 株式会社エネコートテクノロジーズ | 2025-05-30 | — | — | WO | disclosed |
| CN-119487998-A | Photoelectric conversion unit | 株式会社安能科多科技 | 2025-02-18 | — | — | CN | disclosed |
| US-20250026769-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-01-23 | — | — | US | disclosed |
| CN-115232090-B | 6-Substituted dihydrobenzo [ e ] [1,2,3] oxathiazine 2, 2-dioxide compound and preparation and application thereof | 杭州市第七人民医院 | 2024-11-19 | — | — | CN | disclosed |
| WO-2006105442-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
| EP-1675847-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | Adolor Corporation (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060025460-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
| WO-2006009869-A1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050159438-A1 | Spirocyclic heterocyclic derivatives and methods of their use | ADOLOR CORPORATION | 2005-07-21 | — | — | US | disclosed |
| US-6919382-B2 | Preparation and uses of conjugated solid supports for boronic acids | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2005-07-19 | — | — | US | disclosed |
| WO-2005033073-A2 | SPIROCYCLIC HETEROCYCLIC DERIVATIVES AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20030044840-A1 | Preparation and uses of conjugated solid supports for boronic acids | GOVERNORS OF THE UNIVERSITY OF ALBERTA, THE (CA) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421257-B2 | Compositions and methods for inhibiting group II intron RNA | NSUN2, RBM22, RNGTT | HPGD 2326/4885ALDH1A1 2984/4885MAPT 3943/4885 |
| US-20030044840-A1 | Preparation and uses of conjugated solid supports for boronic acids | SLC43A1, SBDS, SLC7A5 | HPGD 3136/4885ALDH1A1 1529/4885MAPT 3821/4885 |
| US-20060025460-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | BCL3, BCL2, BCLAF1 | HPGD 2335/4885ALDH1A1 3755/4885MAPT 3860/4885 |
| US-20250026769-A1 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | POT1, PARP15, TERT | HPGD 1029/4885ALDH1A1 2733/4885MAPT 1601/4885 |
| US-20050159438-A1 | Spirocyclic heterocyclic derivatives and methods of their use | OPRK1, OPRD1, OPRL1 | HPGD 118/4885ALDH1A1 259/4885MAPT 3610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.